{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:46Z","timestamp":1790707246849,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007452","name":"Ministry of Health of China | Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750"],"award-info":[{"award-number":["320.6750"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403743"],"award-info":[{"award-number":["82403743"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02632-5","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:53:30Z","timestamp":1776261210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4\/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)"],"prefix":"10.1038","volume":"11","author":[{"given":"Huai-liang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danmei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8543-6636","authenticated-orcid":false,"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuikui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3752-8506","authenticated-orcid":false,"given":"Qiufan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-5780","authenticated-orcid":false,"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2632_CR1","doi-asserted-by":"crossref","unstructured":"Freddie, B. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","DOI":"10.3322\/caac.21834"},{"key":"2632_CR2","doi-asserted-by":"crossref","unstructured":"Laura, A. et al. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J. Clin. 73, 480\u2013515 (2023).","DOI":"10.3322\/caac.21777"},{"key":"2632_CR3","doi-asserted-by":"crossref","unstructured":"Cynthia, X. et al. Mechanisms of aromatase inhibitor resistance. Nat. Rev. Cancer 15, 261\u2013275 (2015).","DOI":"10.1038\/nrc3920"},{"key":"2632_CR4","doi-asserted-by":"crossref","unstructured":"Ciara Catherine, O. S., Robert, C., Matthew Philip, G. & John, R. Cyclin-dependent kinase 4\/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review. JAMA Oncol. 9, 1273\u20131282 (2023).","DOI":"10.1001\/jamaoncol.2023.2000"},{"key":"2632_CR5","unstructured":"Seth, A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 10, 1174\u20131193 (2020)."},{"key":"2632_CR6","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.7150\/thno.95619","volume":"14","author":"HL Wu","year":"2024","unstructured":"Wu, H. L., Zhou, H. X., Chen, L. M. & Wang, S. S. Metronomic chemotherapy in cancer treatment: new wine in an old bottle. Theranostics 14, 3548\u20133564 (2024).","journal-title":"Theranostics"},{"key":"2632_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrclinonc.2015.131","volume":"12","author":"E Munzone","year":"2015","unstructured":"Munzone, E. & Colleoni, M. Clinical overview of metronomic chemotherapy in breast cancer. Nat. Rev. Clin. Oncol. 12, 631\u2013644 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2632_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.breast.2019.07.006","volume":"48","author":"ME Cazzaniga","year":"2019","unstructured":"Cazzaniga, M. E. et al. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: final results of the VICTOR-6 study. Breast 48, 7\u201316 (2019).","journal-title":"Breast"},{"key":"2632_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10549-018-5024-3","volume":"173","author":"J Li","year":"2019","unstructured":"Li, J. et al. Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial. Breast Cancer Res. Treat. 173, 407\u2013415 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"2632_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clbc.2013.09.003","volume":"14","author":"LS Schwartzberg","year":"2014","unstructured":"Schwartzberg, L. S. et al. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin. Breast Cancer 14, 13\u201319 (2014).","journal-title":"Clin. Breast Cancer"},{"key":"2632_CR11","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1200\/JCO.24.00938","volume":"43","author":"RX Hong","year":"2025","unstructured":"Hong, R. X. et al. Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: the phase III MECCA trial. J. Clin. Oncol. 43, 1314\u20131324 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2632_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41586-023-06112-6","volume":"619","author":"KK Sinha","year":"2023","unstructured":"Sinha, K. K., Bilokapic, S., Du, Y., Malik, D. & Halic, M. Histone modifications regulate pioneer transcription factor cooperativity. Nature 619, 378\u2013384 (2023).","journal-title":"Nature"},{"key":"2632_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40164-020-00197-9","volume":"10","author":"Z Wu","year":"2021","unstructured":"Wu, Z., Nicoll, M. & Ingham, R. J. AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical Hodgkin lymphoma and ALK+\u2009ALCL. Exp. Hematol. Oncol. 10, 4 (2021).","journal-title":"Exp. Hematol. Oncol."},{"key":"2632_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrclinonc.2013.42","volume":"10","author":"N Azad","year":"2013","unstructured":"Azad, N., Zahnow, C. A., Rudin, C. M. & Baylin, S. B. The future of epigenetic therapy in solid tumours-lessons from the past. Nat. Rev. Clin. Oncol. 10, 256\u2013266 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2632_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3324\/haematol.2023.283266","volume":"109","author":"T Kawata","year":"2024","unstructured":"Kawata, T. et al. Tucidinostat restores CCR4 expression in adult T-cell leukemia\/lymphoma. Haematologica 109, 1007\u20131009 (2024).","journal-title":"Haematologica"},{"key":"2632_CR16","doi-asserted-by":"crossref","unstructured":"Mu-Qi, S. et al. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol. Oncol. 17, 37 (2024).","DOI":"10.1186\/s13045-024-01551-8"},{"key":"2632_CR17","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1535-7163.MCT-13-0345","volume":"12","author":"GJ Sabnis","year":"2013","unstructured":"Sabnis, G. J., Goloubeva, O. G., Kazi, A. A., Shah, P. & Brodie, A. H. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol. Cancer Ther. 12, 2804\u20132816 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"2632_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02598-5","volume":"20","author":"P Zhang","year":"2022","unstructured":"Zhang, P. et al. Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Med. 20, 435 (2022).","journal-title":"BMC Med."},{"key":"2632_CR19","doi-asserted-by":"publisher","first-page":"e763","DOI":"10.1093\/oncolo\/oyae033","volume":"29","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. Tucidinostat plus exemestane as a neoadjuvant in early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Oncologist 29, e763\u2013e770 (2024).","journal-title":"Oncologist"},{"key":"2632_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang, Z. et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 806\u2013815 (2019).","journal-title":"Lancet Oncol."},{"key":"2632_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.23.00456","volume":"42","author":"FC Bidard","year":"2024","unstructured":"Bidard, F. C. et al. Overall survival with circulating tumor cell count-driven choice of therapy in advanced breast cancer: a randomized trial. J. Clin. Oncol. 42, 383\u2013389 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2632_CR22","doi-asserted-by":"crossref","unstructured":"Belinda, K. et al. ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1-mutant breast cancer. Cancer Discov. 14, 274\u2013289 (2023).","DOI":"10.1158\/2159-8290.CD-22-1387"},{"key":"2632_CR23","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1158\/1078-0432.CCR-23-0956","volume":"29","author":"J Pascual","year":"2023","unstructured":"Pascual, J. et al. Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive\/HER2-negative metastatic breast cancer patients. Clin. Cancer Res. 29, 4166\u20134177 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2632_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65432-5","volume":"16","author":"MJM Magbanua","year":"2025","unstructured":"Magbanua, M. J. M. et al. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nat. Commun. 16, 9945 (2025).","journal-title":"Nat. Commun."},{"key":"2632_CR25","doi-asserted-by":"crossref","unstructured":"Mamann, A. et al. Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive\/HER2-negative breast cancer. Ann. Oncol. 36, 1342\u20131355 (2025).","DOI":"10.1016\/j.annonc.2025.06.015"},{"key":"2632_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano, A. et al. Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist Updat 76, 101103 (2024).","journal-title":"Drug Resist Updat"},{"key":"2632_CR27","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer, E. L. et al. PACE: a randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-positive\/human epidermal growth factor receptor-negative metastatic breast cancer. J. Clin. Oncol. 42, 2050\u20132060 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2632_CR28","doi-asserted-by":"crossref","unstructured":"Rugo, H. S. et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 25, e629\u2013e638 (2024).","DOI":"10.1016\/S1470-2045(24)00673-9"},{"key":"2632_CR29","unstructured":"Francois-Clement, B. et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J. Clin. Oncol. 40, 3246\u20133256 (2022)."},{"key":"2632_CR30","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky, K. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J. Clin. Oncol. 41, 4004\u20134013 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2632_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"FC Bidard","year":"2022","unstructured":"Bidard, F. C. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 23, 1367\u20131377 (2022).","journal-title":"Lancet Oncol."},{"key":"2632_CR32","doi-asserted-by":"crossref","unstructured":"Wafaa, S. et al. Impact of HDAC6-mediated progesterone receptor expression on the response of breast cancer cells to hormonal therapy. Eur. J. Pharmacol. 983, 177001 (2024).","DOI":"10.1016\/j.ejphar.2024.177001"},{"key":"2632_CR33","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.21873\/anticanres.14356","volume":"40","author":"F Nouri Emamzadeh","year":"2020","unstructured":"Nouri Emamzadeh, F. et al. Modulation of estrogen \u03b1 and progesterone receptors in triple negative breast cancer cell lines: the effects of vorinostat and indole-3-carbinol in vitro. Anticancer Res 40, 3669\u20133683 (2020).","journal-title":"Anticancer Res"},{"key":"2632_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41420-021-00635-5","volume":"7","author":"SY Loo","year":"2021","unstructured":"Loo, S. Y. et al. Epigenetic derepression converts PPAR\u03b3 into a druggable target in triple-negative and endocrine-resistant breast cancers. Cell Death Discov. 7, 265 (2021).","journal-title":"Cell Death Discov."},{"key":"2632_CR35","first-page":"309","volume":"26","author":"C Puppin","year":"2011","unstructured":"Puppin, C., Puglisi, F., Pandolfi, M., Di Loreto, C. & Damante, G. Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines. Oncol. Rep. 26, 309\u2013314 (2011).","journal-title":"Oncol. Rep."},{"key":"2632_CR36","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.18632\/oncotarget.6802","volume":"7","author":"M Terranova-Barberio","year":"2016","unstructured":"Terranova-Barberio, M. et al. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget 7, 7715\u20137731 (2016).","journal-title":"Oncotarget"},{"key":"2632_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/annonc\/mdn592","volume":"20","author":"C Andreetta","year":"2009","unstructured":"Andreetta, C. et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann. Oncol. 20, 265\u2013271 (2009).","journal-title":"Ann. Oncol."},{"key":"2632_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.breast.2022.10.018","volume":"66","author":"J Zhou","year":"2022","unstructured":"Zhou, J. et al. Clinical outcomes of tucidinostat-based therapy after prior CDK4\/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Breast 66, 255\u2013261 (2022).","journal-title":"Breast"},{"key":"2632_CR39","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","volume":"13","author":"B Xu","year":"2023","unstructured":"Xu, B. et al. Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Acta Pharm. Sin. B 13, 2250\u20132258 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"2632_CR40","doi-asserted-by":"crossref","unstructured":"Munzone, E. et al. Efficacy of metronomic oral vinorelbine, cyclophosphamide, and capecitabine vs weekly intravenous paclitaxel in patients with estrogen receptor-positive, ERBB2-negative metastatic breast cancer: final results from the phase 2 METEORA-II randomized clinical trial. JAMA Oncol. 9, 1267\u20131272 (2023).","DOI":"10.1001\/jamaoncol.2023.2150"},{"key":"2632_CR41","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10549-016-4009-3","volume":"160","author":"ME Cazzaniga","year":"2016","unstructured":"Cazzaniga, M. E. et al. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res. Treat. 160, 501\u2013509 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"2632_CR42","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, F. et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann. Oncol. 32, 208\u2013217 (2020).","DOI":"10.1016\/j.annonc.2020.11.011"},{"key":"2632_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.21037\/tbcr-23-9","volume":"4","author":"Y Yuan","year":"2023","unstructured":"Yuan, Y. et al. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR(+)HER2(-) metastatic breast cancer. Transl. Breast Cancer Res. 4, 10 (2023).","journal-title":"Transl. Breast Cancer Res."},{"key":"2632_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1158\/1078-0432.CCR-22-1281","volume":"29","author":"J Albanell","year":"2023","unstructured":"Albanell, J. et al. Palbociclib rechallenge for hormone receptor-positive\/HER-negative advanced breast cancer: findings from the phase II BioPER trial. Clin. Cancer Res. 29, 67\u201380 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2632_CR45","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1158\/1078-0432.CCR-20-2114","volume":"27","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Phase I\/II trial of exemestane, ribociclib, and everolimus in women with HR(+)\/HER2(-) advanced breast cancer after progression on CDK4\/6 inhibitors (TRINITI-1). Clin. Cancer Res. 27, 4177\u20134185 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2632_CR46","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2632_CR47","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","volume":"32","author":"DJ Slamon","year":"2021","unstructured":"Slamon, D. J. et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann. Oncol. 32, 1015\u20131024 (2021).","journal-title":"Ann. Oncol."},{"key":"2632_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/djaa087","volume":"113","author":"B O\u2019Leary","year":"2021","unstructured":"O\u2019Leary, B. et al. Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer. J. Natl. Cancer Inst. 113, 309\u2013317 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"2632_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin, O. & Oren, M. Drugging p53 in cancer: one protein, many targets. Nat. Rev. Drug Discov. 22, 127\u2013144 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2632_CR50","doi-asserted-by":"crossref","unstructured":"Lorenzo, G. et al. Circulating tumor cells dynamics after CDK4\/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study. Clin. Cancer Res. 31, 4510\u20134517 (2025).","DOI":"10.1158\/1078-0432.CCR-25-0327"},{"key":"2632_CR51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"2632_CR52","unstructured":"Members, C. N. Database resources of the National Genomics Data Center, China National Center for Bioinformation in 2026. Nucleic Acids Res. 54, D28 (2025)."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02632-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:53:42Z","timestamp":1776261222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02632-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2632"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02632-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}